Richard Steingart, MD
Hematology · Springfield, MANPI 1740202076
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,767 of the $19,088 with a category attached, or 93.1%. 13 manufacturers reported payments, led by Sanofi at 40.4% of the total.
Across 22 payments — averaging $867.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
- Novartis$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Recordati_rare_diseases_inc.$2K
- Pharmacyclics LLC, An Abbvie Company$2K
- AstraZeneca$367
- plus $644 from 7 others
What the payments were for
- Consulting fees$17,76793%
- Travel & lodging$1301%
- Food & beverage$1,0596%
- Education$1331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 4 | $7,716 |
| Novartis | 2 | $4,069 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,409 |
| Recordati_rare_diseases_inc. | 1 | $2,205 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $1,679 |
| AstraZeneca | 3 | $367 |
| Syndax Pharmaceuticals, Inc. | 1 | $150 |
| Amgen | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| AbbVie | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Pfizer | 3 | $33 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,088 in reported general payments places this provider in the 70th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 77 | $1,761,575 |
| ImbruvicaIbrutinib | 77 | $1,251,708 |
| RevlimidLenalidomide | 46 | $832,220 |
| CerdelgaEliglustat Tartrate | 25 | $789,776 |
| Lenalidomide | 75 | $759,139 |
| BrukinsaZanubrutinib | 60 | $638,797 |
| JakafiRuxolitinib Phosphate | 45 | $625,588 |
| VonjoPacritinib Citrate | 23 | $550,905 |
| CalquenceAcalabrutinib Maleate | 54 | $541,524 |
| ScemblixAsciminib Hydrochloride | 11 | $239,853 |
| NinlaroIxazomib Citrate | 16 | $202,360 |
| VenclextaVenetoclax | 22 | $191,246 |
| Imatinib Mesylate | 33 | $37,387 |
| OxycontinOxycodone Hcl | 108 | $36,901 |
| RetacritEpoetin Alfa-Epbx | 21 | $35,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $100 | $1,761,57577 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $1,679 | $1,251,70877 claims |
| SanofiCerdelga | $7,716 | $789,77625 claims |
| AstraZenecaCalquence | $367 | $541,52454 claims |
| NovartisScemblix | $4,069 | $239,85311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $2,409 | $202,36016 claims |
| AbbVieVenclexta | $100 | $191,24622 claims |
| PfizerRetacrit, Eliquis | $33 | $63,87442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 hematology providers in Massachusetts.
Other hematology in Springfield
- Chandravathi LokeSpringfield$141
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- David WagesSouth Boroulh$454K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.